1. Home
  2. RUMBW vs WGSWW Comparison

RUMBW vs WGSWW Comparison

Compare RUMBW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc. Warrant

RUMBW

Rumble Inc. Warrant

N/A

Current Price

$1.18

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

N/A

Current Price

$0.01

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
RUMBW
WGSWW
Founded
2013
2017
Country
United States
United States
Employees
135
1300
Industry
Computer Software: Prepackaged Software
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RUMBW
WGSWW
Price
$1.18
$0.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.7K
61.3K
Earning Date
03-28-2025
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$85,651,775.00
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.36
50.79
52 Week Low
$0.90
$0.01
52 Week High
$4.25
$0.29

Technical Indicators

Market Signals
Indicator
RUMBW
WGSWW
Relative Strength Index (RSI) 35.32 34.65
Support Level N/A $0.01
Resistance Level $2.81 $0.02
Average True Range (ATR) 0.19 0.00
MACD -0.01 0.00
Stochastic Oscillator 39.02 10.48

Price Performance

Historical Comparison
RUMBW
WGSWW

About RUMBW Rumble Inc. Warrant

Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: